In short
Elamipretide Trihydrochloride is currently being studied in clinical trials as a potential treatment for dry age-related macular degeneration (dry AMD). This article explores the ongoing research, focusing on a Phase 3 clinical trial called ReNEW, which aims to evaluate the efficacy, safety, and pharmacokinetics of subcutaneous injections of Elamipretide in patients with dry AMD.
At a glance
- Drug Name
- Elamipretide Trihydrochloride
- Trial Name
- ReNEW (Phase 3 Clinical Trial)
- Condition Studied
- Dry Age-Related Macular Degeneration (Dry AMD)
- Administration Method
- Daily subcutaneous injections
- Trial Duration
- 96 weeks
- Primary Objective
- Evaluate efficacy in slowing photoreceptor loss
- Secondary Objectives
- Assess safety, tolerability, and pharmacokinetics
- Key Inclusion Criteria
- Adults ≥55 years with dry AMD and photoreceptor loss
- Primary Endpoint
- Rate of change in macular area of photoreceptor loss at Week 48
- Key Secondary Endpoints
- Changes in photoreceptor loss at Weeks 72 and 96, improvements in low luminance visual acuity
What is Elamipretide?
Elamipretide, also known by its scientific name elamipretide trihydrochloride or its product code MTP-131, is an investigational drug being developed by Stealth BioTherapeutics Inc. It is classified as an aromatic-cationic tetrapeptide, which is a type of small protein molecule. Elamipretide represents a new class of drugs with a unique mechanism of action, making it a promising candidate for treating various conditions, particularly those affecting the eyes.
Target Condition: Dry Age-Related Macular Degeneration
The primary focus of the current clinical trial is to evaluate elamipretide's effectiveness in treating dry age-related macular degeneration (dry AMD). Dry AMD is a common eye condition that affects older adults, causing a gradual loss of central vision. It occurs when the central part of the retina, called the macula, deteriorates over time. This can significantly impact a person's ability to read, recognize faces, and perform daily activities.
Clinical Trial Details
The clinical trial for elamipretide, known as "ReNEW," is a Phase 3 study designed to evaluate the drug's efficacy, safety, and pharmacokinetics in patients with dry AMD. Here are some key details about the trial:
- It is a randomized, double-masked, placebo-controlled study, which means participants are randomly assigned to either the elamipretide group or a placebo group, and neither the patients nor the researchers know who is receiving the actual drug.
- The trial will last for approximately 96 weeks (about 2 years).
- Participants will be randomized in a 2:1 ratio, meaning two-thirds of the participants will receive elamipretide, while one-third will receive a placebo.
How Elamipretide is Administered
Elamipretide is administered as a subcutaneous injection, which means it is injected just under the skin. The drug comes in the form of a solution for injection. Patients or their caregivers will be trained to administer the drug daily and will be required to keep a dosing diary to record the time and location of each injection.
Eligibility Criteria
To participate in the trial, patients must meet certain criteria, including:
- Being 55 years of age or older
- Having at least one eye with dry AMD and photoreceptor loss, as determined by specific imaging techniques
- Women of childbearing potential and men with partners of childbearing potential must agree to use effective birth control methods
- Being able to administer the study drug and comply with all trial procedures
Certain conditions may exclude a person from participating, such as having concurrent eye diseases or other medical conditions that might interfere with the study results.
Potential Benefits
The main goals of the study are to determine if elamipretide can:
- Slow down the rate of photoreceptor loss in the macula, which could potentially slow the progression of dry AMD
- Improve low-light visual acuity, which is often affected in patients with dry AMD
These potential benefits could significantly impact patients' quality of life by preserving their vision for longer periods.
Safety Considerations
As with any clinical trial, the safety and tolerability of elamipretide are being closely monitored. The study includes a 4-week safety follow-up period after the 96-week treatment period to assess any potential long-term effects of the drug. It's important to note that as an investigational drug, not all potential side effects of elamipretide may be known at this time.
Other Potential Applications of Elamipretide
While this trial focuses on dry AMD, elamipretide is being studied for other conditions as well. Previous and ongoing studies have explored its potential in treating:
- Heart conditions, including heart failure and reperfusion injury following heart attacks
- Primary mitochondrial diseases, which are genetic disorders affecting cellular energy production
- Primary mitochondrial myopathy, a type of muscle disease
These diverse applications suggest that elamipretide may have broad potential in treating conditions related to cellular energy dysfunction.